Longitude Prize on ALS

The £7.5 million (~$10 million) Longitude Prize on ALS incentivises the use of AI-based approaches to transform drug discovery for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND).

Meet our 20 Discovery Award teams!

Find out who has been selected for Stage 1 of the of the Longitude Prize on ALS.

Discovery Award Teams

Overview of the Prize

Interested in learning more about the Prize? Watch this to get an overview of how it works.

Learn more about the Longitude Prize on ALS Learn more about the funders and partners

Timeline of the Prize

The Longitude Prize on ALS will run for five years and will comprise three key stages: Discovery, Prioritise and Validate

25 June 2025

Prize opened for applications

3 December 2025

Stage 1 applications closed

December 2025 - March 2026

Assessment and judging (Stage 1)

Our panel of expert assessors and judges reviewed applications against the eligibility and judging criteria.

April 2026 - December 2026

Stage One: Discovery

20 teams receive £100,000 to identify new high potential therapeutic targets.

January 2027 - April 2027

Assessment and judging (Stage 2)

Our panel of expert assessors and judges will review applications against the eligibility and judging criteria.

May 2027 - April 2028

Stage Two: Prioritise

10 teams will receive a further £200,000 to build the evidence base for their proposed therapeutic targets in silico and in the lab.

April 2028

Stage 3 applications close

May 2028 - August 2028

Assessment and judging (Stage 3)

Our panel of expert assessors and judges will review applications against the eligibility and judging criteria.

September 2028 - August 2030

Stage Three: Validate

Five teams will receive £500,000 to undertake validation of the highest potential identified targets in the wet lab.

August 2030

Winner applications close

September 2030 - December 2030

Assessment and judging (winner stage)

Our panel of expert assessors and judges will review applications against the eligibility and judging criteria and select a winner for the Prize.

January - February 2031

Winner's Announcement

One winning team will be announced, winning £1,000,000 for finding the target with the strongest evidence of therapeutic potential.

Interested in the Prize?

If you want to keep up with our progress, join our mailing list

Join our mailing list